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OPEN

Acute levodopa dosing around-the-clock ameliorates REM
sleep without atonia in hemiparkinsonian rats
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Vishakh Iyer 1,6, Quynh Vo2,6, Anthony Mell3,6, Siven Chinniah3, Ashley Zenerovitz3, Kala Venkiteswaran3, Allen R. Kunselman4,
Jidong Fang5 and Thyagarajan Subramanian3*
Rapid-eye-movement (REM) sleep without atonia (RSWA), a marker of REM sleep behavior disorder (RBD), is frequently comorbid
with Parkinson’s disease (PD). Although rodent models are commonly used for studying PD, the neurobiological and behavioral
correlates of RBD remain poorly understood. Therefore, we developed a behavior-based criteria to identify RSWA in the
hemiparkinsonian rat model of PD. Video recordings of rats were analyzed, to develop a criteria consisting of behavioral signs that
occurred during polysomnographically conﬁrmed epochs of sleep-wake stages. The sleep-slouch, a postural shift of the body or
head caused only by gravity, was identiﬁed as a unique behavioral sign of REM sleep onset and was altered in hemiparkinsonian
rats during RSWA. There was a signiﬁcant correlation between the behavior-based criteria and polysomnograms for all sleep-wake
stages in control but not hemiparkinsonian rats indicating a deterioration of sleep-wake architecture in parkinsonism. We then
tested the efﬁcacy of levodopa in ameliorating RSWA using intermittent and around-the-clock (ATC) dosing regimens. ATC
levodopa dosing at 4 mg/kg for 48 h caused a signiﬁcant reduction of RSWA as measured by polysomnography and the behavioralbased criteria along with an amelioration of forelimb motor deﬁcits. Our ﬁndings show that the phenomenological correlates of
RSWA can be reliably characterized in the hemiparkinsonian rat model. ATC levodopa administration ameliorates RSWA in this
model without deleterious consequences to the overall sleep-wake architecture and therapeutic beneﬁts for parkinsonian motor
deﬁcits. These ﬁndings suggest that further study may allow for the application of a similar approach to treat RBD in PD patients.
npj Parkinson’s Disease (2019)5:27 ; https://doi.org/10.1038/s41531-019-0096-2

INTRODUCTION
Disturbances of sleep are well documented in Parkinson’s disease
(PD) and are estimated to occur in 60–90% of all PD patients.1–4
Rapid-eye-movement sleep behavior disorder (RBD) is one of the
most common and disabling sleep disturbances associated with
PD and is characterized by a loss of muscle atonia during rapideye-movement (REM) sleep and dream enactments.5–8 Therefore,
the occurrence of REM sleep without atonia (RSWA) is considered
the prototypical marker of RBD.9 PD patients with RBD report
signiﬁcant morbidity due to fatigue, excessive daytime sleepiness,
injuries related to dream enactments, and ﬂuctuating efﬁcacy of
PD therapeutics.10–13 Studies have also shown that the morbidity
of sleep dysfunction signiﬁcantly affects the quality of life of PD
patients and may exceed the impact of the motor impairment and
other complications.10,14 Finally, RBD symptoms frequently predate the diagnosis of PD motor symptoms and has been
investigated as a putative biomarker for pre-clinical PD.4,5,15–18
Taken together, these factors underscore the need for a preclinical model that recapitulates the phenomenology of RSWA in
PD and help close the major gap in this area of unmet therapeutic
need.14,19
Although rodents are commonly used to model PD, few studies
have investigated sleep dysfunctions in these pre-clinical models.
Current pre-clinical models of sleep disorders in rodents utilize a
combination of electroencephalography (EEG) and electromyography (EMG) to classify sleep-wake stages. Rodent sleep is
typically divided into three principal categories: awake, REM sleep,
and non-REM sleep (NREM).20,21 Unlike human polysomnography,

most rodent sleep studies do not make use of time-locked video
recordings or well-delineated behavior-based criteria for identifying sleep stages or its dysfunctions. Rodent sleep architecture also
lacks many of the characteristic hallmarks commonly found in
human sleep recordings. Therefore, rodent sleep recordings
present a unique challenge in identifying sleep disorders that
are associated with movement such as RBD, as EMG becomes
unreliable as a marker for RBD-associated movement. Previously,
we have shown that the sleep architecture in the unilateral
6-hydroxydopamine (6-OHDA) lesioned hemiparkinsonian rat
model of PD, an animal model that has contributed to the
development of most of the medications in current use for PD,
resembles that of human PD patients with RBD.22 Here we
demonstrate that this animal model exhibits RBD like behavioral
features and validated a set of behavior-based criteria for sleepwake stages that is correlated with rat sleep architecture to
reliably assess RSWA.
Most treatments currently available for RBD in PD patients like
clonazepam and melatonin are considered suboptimal due to
their variable efﬁcacy and side effects such as sedation, motor
incoordination, confusion, memory dysfunction etc.23 In contrast,
levodopa one of the most commonly prescribed anti-PD medication has been shown to be effective in ameliorating RBD in several
studies especially when RBD precedes the onset of the motor
symptoms of PD.14,24,25 The effects of levodopa in patients who
only present with RBD and do not develop PD in their lifetime is
not discussed here. In such patients, levodopa did not meet
evidence-based data to be recommended as a treatment.23 All
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current PD patients, however, will receive levodopa in their
lifetime and exposure to this medication is unavoidable in
contemporary medicine as it is by far the most effective
pharmacotherapy for PD. Unfortunately, long-term use of intermittent oral levodopa causes disabling motor complications in
most PD patients. A recent review of clinical trials, however, has
shown that levodopa dosing, administration route, and regimen
may be critical in affecting the onset of these medication-induced
complications and novel dosing regimens with strict compliance
may be able to overcome their side effects.26
The advent of extended-release oral levodopa formulations and
intrajejunal pump-based levodopa administration methods have
permitted longer and more continuous dosing regimens. Such
treatments with continuous or around-the-clock (ATC) dosing may
help avoid the medication-induced complications of levodopa.
However, the efﬁcacy of such dosing regimens remains largely
unexplored in pre-clinical models of PD. Therefore, we investigated whether RSWA in the 6-OHDA hemiparkinsonian rodent
model of PD is responsive to levodopa therapy when administered ATC. Our results indicate that ATC dosing of levodopa
mitigates both motor symptoms like forelimb bradykinesia and
non-motor symptoms such as RSWA without affecting the overall
architecture of sleep-wake stages in this rat model. Our ﬁndings
suggest that such an ATC dosing regimen with continuous
delivery of levodopa could be a potential experimental therapeutic strategy for RBD in PD patients.
RESULTS
ATC levodopa dosing leads to accurate classiﬁcation of
hemiparkinsonian rats comparable to unlesioned controls
The accuracy of the behavior-based criteria proposed here was
tested by comparing the average scores of the two independent
blinded raters with polysomnography (PSG) recordings for all
sleep-wake stage (Wake, NREM, and REM) classiﬁcation. To
compute the inter-rater reliability of the criteria, classiﬁcation
was also compared between the two raters for all sleep-wake
stages. In unlesioned control rats, the sleep-wake stage classiﬁcation using the behavior-based criteria (Average of Scorer 1 and

Scorer 2) showed a good agreement (concordance correlation
coefﬁcient (CCC) > 0.8) compared with PSG for all sleep-wake
stages (Fig. 1a, Table 1). The inter-rater reliability of the criteria
also showed good agreement between the two raters (CCC >0.8)
for all sleep-wake stages (Fig. 1b, Table 1). Graphed sleep
proﬁles between the raters and PSG also showed close matches
in the sleep-wake stage classiﬁcation (Fig. 1c). In untreated
hemiparkinsonian rats, there was poor agreement (CCC <0.8)
between the behavior-based criteria compared with the PSG for
all sleep-wake stages (Fig. 2a, Table 2). Graphed sleep proﬁles
showed several false-positive and false-negative identiﬁcations
of REM periods when comparing the behavior-based criteria to
PSG (Fig. 2b). However, following ATC treatment of levodopa at
4 mg/kg, hemiparkinsonian rats showed good levels of agreement (CCC <0.8) between the behavior-based criteria compared
with PSG for all sleep-wake stages (Fig. 2c, Table 2). Graphed
sleep proﬁles also showed close matches in the sleep-wake
stage classiﬁcation (Fig. 2d).
Video recordings show qualitative improvements in
hemiparkinsonian rat sleep-slouch
Evaluation of video recordings of control and hemiparkinsonian
rats showed qualitative differences in the sleep-slouch, a unique
and characteristic behavior that occurs during the onset of REM
sleep. In control rats, the sleep-slouch was seen in real time (at
normal playback speed) as it occurred quickly and the drop of the
animal’s body due to gravity was observed. In contrast, in
hemiparkinsonian rats, the sleep-slouches were subtle and cannot
be seen in real time as they occur slowly and are therefore less
discernible. A closer examination of the video recordings showed
that while behaviors characteristic of REM sleep are preserved in
hemiparkinsonian rats, the quality of these behaviors became
more subtle as reﬂected in a decreased accuracy in sleepclassiﬁcation using the behavior-based criteria. However, following
levodopa treatment, the sleep-slouch qualitatively improved in
hemiparkinsonian rats, occurred over faster timescales, was clear
and was comparable to those seen in the control rats
(Supplementary Video 1).

Fig. 1 Comparison of sleep-wake stage classiﬁcation between polysomnography and the behavior-based criteria and between two separate
blinded raters in control rats. a In control rats (n = 10), there was good agreement between the average of the raters (Average of Scorer 1 and
Scorer 2) and polysomnography (PSG) indicating the high face validity of the behavior-based criteria for classiﬁcation of all sleep-wake stages
(Wake, NREM, and REM). b Comparisons between raters (Scorer 1 vs. Scorer 2) also showed a good level of agreement indicating high interrater reliability of the behavior-based criteria. c A 1-h graphed sleep proﬁle comparing classiﬁcation between the raters and PSG also showed
close matches in all sleep-wake stages, with all REM periods correctly identiﬁed by the raters.
npj Parkinson’s Disease (2019) 27
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Table 1. Concordance correlation coefﬁcient (CCC) and 95% CI measuring agreement between PSG and behavior-based criteria and between two
blinded raters in control rats.
Sleep-wake stage
% Wake
% NREM
% REM

Comparison

Concordance correlation
coefﬁcient (CCC)

95% Conﬁdence interval (CI)

PSG vs. Behavior-based criteria

0.984

0.938, 0.996

Scorer 1 vs. Scorer 2

0.943

0.819, 0.983

PSG vs. Behavior-based criteria

0.983

0.934, 0.996

Scorer 1 vs. Scorer 2

0.922

0.769, 0.975

PSG vs. Behavior-based criteria
Scorer 1 vs. Scorer 2

0.971
0.856

0.906, 0.991
0.589, 0.955

In control rats (n = 10), there was good agreement between the polysomnography (PSG) vs. the behavior-based criteria and between the two blinded raters
(all CCC >0.8). Behavior scores for comparison against PSG were obtained using the average scores of the two raters. These results are demonstrative of the of
the face-validity and inter-rater reliability of the criteria

Fig. 2 Comparison of sleep-wake stage classiﬁcation between untreated and levodopa-treated groups using the behavior-based criteria and
polysomnography in hemiparkinsonian rats. a In untreated hemiparkinsonian rats (n = 5), there was poor agreement between the behaviorbased criteria compared with polysomnography (PSG) for all sleep-wake stages, which was indicative of the decline in quality of the behaviors
used to apply the criteria. b A 1-h graphed sleep proﬁle comparing classiﬁcation between the raters and the polysomnograms showed several
false-positive and false-negative identiﬁcations of REM periods by either or both raters (circled). c ATC levodopa at 4 mg/kg in treated
hemiparkinsonian rats (n = 4) helped alleviate the adverse behavioral changes caused by lesioning as indicated by the good levels of
agreement between the behavior-based criteria compared with PSG for all sleep-wake stages post levodopa treatment. d A 1-h graphed sleep
proﬁle in a levodopa-treated hemiparkisonian rat also showed close matches in all sleep-wake stages similar to that of a control rat.

Acute ATC dosing of levodopa improves RSWA in
hemiparkinsonian rats
ATC dosing of levodopa at 4 mg/kg in hemiparkinsonian rats
(17.3 ± 2.2) compared to baseline (30.2 ± 0.9) resulted in a signiﬁcant
decrease in RSWA (F (3, 18) = 4.543, p = 0.0398) (Fig. 3). In contrast,
no statistically signiﬁcant differences were observed with 2 mg/kg
two times per day (BID) (29.6 ± 6.3), 2 mg/kg three times per day
(TID) (31.5 ± 9.5), 2 mg/kg ATC (26.3 ± 3.4), 4 mg/kg BID (22.8 ± 5.3),
and 4 mg/kg TID (25.5 ± 5.0) dosing regimens compared to baseline.
Electrooculograph (EOG) was used to conﬁrm the RSWA observed
and used to differentiate the tonic and phasic REM epochs.
Levodopa dosing regimens did not cause changes in overall sleepwake states
Comparison of the mean percentages of all sleep-wake states
(Wake, NREM, phasic REM, and tonic REM) between baseline and
the six different levodopa dosing regimens showed no statistically
signiﬁcant differences (F (6, 18) = 0.6305, p = 0.7042). This suggests
Published in partnership with the Parkinson’s Foundation

that the arousals caused by variability in number of injections used
to administer levodopa did not cause any signiﬁcant alterations to
the overall sleep architecture in hemiparkinsonian rats (Fig. 4).
ATC dosing of levodopa improves impaired limb motor functions
in hemiparkinsonian rats
The vibrissae-evoked forelimb placement following 4 mg/kg ATC
dosing (86.4 ± 7.5) compared to the post-lesion baseline (14.4 ±
8.3) showed a signiﬁcant improvement in affected limb usage
(F (3, 6) = 2.468, p = 0.0075). The 2 mg/kg ATC (52.4 ± 19.5) dosing
showed an upward trend but did not reach levels of statistical
signiﬁcance (Fig. 5). The unaffected forelimb usage showed no
changes in usage in any rats. The development of drug-induced
dyskinesias interfered with the ability to conduct the vibrissaeevoked forelimb placement test in hemiparkinsonian rats during
the BID and TID testing drug regimens and were therefore
excluded from analysis. Control rats did not show any deﬁcits on
the test (data not shown).
npj Parkinson’s Disease (2019) 27
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Table 2.

Concordance correlation coefﬁcient (CCC) and 95% CI measuring agreement in untreated and levodopa-treated hemiparkinsonian between
PSG and behavior-based criteria.

Sleep-wake stage

Comparison

Concordance correlation
coefﬁcient (CCC)

95% Conﬁdence interval (CI)

Untreated hemiparkinsonian rats
% Wake

PSG vs. Behavior-based criteria

0.156

−0.285, 0.543

% NREM

PSG vs. Behavior-based criteria

0.294

−0.344, 0.747

% REM

PSG vs. Behavior-based criteria

0.267

−0.263, 0.673

Levodopa-treated hemiparkinsonian rats
% Wake
PSG vs. Behavior-based criteria

0.967

0.77, 0.996

% REM

PSG vs. Behavior-based criteria

0.961

0.744, 0.995

% REM

PSG vs. Behavior-based criteria

0.997

0.964, 1

20

*

0

Fig. 3 Comparison of mean percentages of tonic REM epochs with
positive muscle activity (RSWA). There was a statistically signiﬁcant
decrease in the percentage of tonic REM epochs with positive
muscle activity (representative of RSWA) using the 4 mg/kg ATC
dosing (*p < 0.05 vs. baseline) in the levodopa-treated hemiparkinsonian rats (n = 4). This decrease was not seen with any other dosing
regimen (BID—two times per day, TID—three times per day, ATC—
around-the-clock every 4 h for 24 h). Box plot shows minimum and
maximum ranges and all data points. Error bars indicate ± s.e.m.

Hemiparkinsonian rats show a profound unilateral loss of
nigrostriatal neurons
Histological examination of hemiparkinsonian rats showed greater
than 95% depletion of dopaminergic neurons in the substantia
nigra on the lesioned side (Fig. 6b) and a dramatic loss of tyrosine
hydroxylase positive ﬁbers in the corresponding striatum (Fig. 6a)
as expected from this PD model. Unbiased stereological estimations on the right substantia nigra and Abercombie corrected
manual counts on the left substantia nigra conﬁrmed these
histological observations. All rats used in this experiment met the
criterion of 95% depletion of nigral neurons. No evidence of
histological lesions in the locus coeruleus, raphe nuclei, sublaterodorsal nucleus, or any areas that have been described previously
in models of RBD was found.27
npj Parkinson’s Disease (2019) 27
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In untreated hemiparkinsonian rats (n = 5), there was poor agreement between the polysomnography (PSG) vs. the behavior-based criteria for all sleep-wake
stages (all CCC <0.8). However, in levodopa-treated hemiparkinsonian rats (n = 4), there was good agreement between the PSG vs. the behavior-based criteria
for all sleep-wake stages (all CCC >0.8). The behavior-based criteria were implemented by a blinded scorer for each group. These results are demonstrative of
the effect of levodopa treatment on improving sleep-wake stage classiﬁcation

Wake

NREM

pREM

tREM

Fig. 4 Comparison of average time in Wake, NREM, phasic REM, and
tonic REM epochs across differing dosing regimens. There were no
statistically signiﬁcant differences in any sleep-wake stage (Wake,
NREM, phasic REM (pREM), and tonic REM (tREM)) irrespective of the
dosing regimen used. This suggests that the differential number of
arousals caused by various drug regimens did not alter the overall
sleep architecture in the treated hemiparkinsonian rats (n = 4). (N.S.
—nonsigniﬁcant, BID—two times per day, TID—three times per day,
ATC—around-the-clock every 4 h for 24 h).

DISCUSSION
To our knowledge, this is the ﬁrst study of the effect of ATC
administration of levodopa on RSWA in the well-studied hemiparkinsonian rat model. Our data provides evidence that RSWA in
the hemiparkinsonian rat model of PD is levodopa responsive if
dosed ATC and that such dosing does not result in overall sleepwake architecture changes. Additionally, we describe here a wellcharacterized behavior-based criteria that helps classify sleepwake stages in both control and treated hemiparkinsonian rats
that exhibit RSWA with accuracy comparable to that of the gold
standard of PSG. Further, we observe behavioral changes in
hemiparkinsonian rats, during REM sleep which could be
potentially combined with PSG to provide a better understanding
Published in partnership with the Parkinson’s Foundation
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of RBD-like behavior in PD rodent models. The sleep-slouch
posture described here is a signiﬁcant marker of the onset of REM
sleep and could potentially parallel akinesia observed during REM
sleep. This posture was less robust and slower in lesioned rats
compared to unlesioned control rats reﬂecting a lack of atonia as a
consequence of parkinsonism. ATC levodopa treatment of
hemiparkinsonian rats led to the restoration of the sleep-slouch
to normal levels suggesting that RWSA is responsive to dopamine
replacement therapy in this model of PD.
RBD is one of the most understudied aspects of the sleep-wake
alterations in animal models of PD (see review in ref. 28). The
unilateral 6-OHDA lesioned hemiparkinsonian rat is a welldescribed preclinical model of PD that has been extensively used
for obtaining critical preclinical safety and efﬁcacy data for all PD
medications in contemporary use.29 This animal model has also
led to a better understanding of the pathophysiology of basal
ganglia dysfunction in PD and is increasingly recognized as a
useful model to study many of the non-motor features of PD
including sleep dysfunctions in PD. Other rat models using

Affected Limb Usage (%)
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Fig. 5 Effects of levodopa treatment on motor symptoms measured
by the vibrissae-evoked forelimb placement test. The affected limb
usage measured using the vibrissae-evoked forelimb placement test
showed a signiﬁcant alleviation of parkinsonian motor deﬁcits at the
4 mg/kg ATC dosing (**p < 0.01 vs. baseline) compared to postlesion baseline scores in levodopa-treated hemiparkinsonian rats
(n = 4). The 2 mg/kg ATC dosing showed a trend toward improvement that did not reach levels of statistical signiﬁcance. Data are
expressed as mean ± s.e.m. (ATC—around-the-clock every 4 h for
24 h).

intracerebroventricular or bilateral striatal injections of 6-OHDA
have also shown a dysregulation of circadian mechanisms caused
by a disruption of dopamine signaling.30,31 However, such models
also cause debilitating disabilities, signiﬁcant morbidity, and
variable mortality, which may contribute to the sleep deﬁcits
seen.31,32 The rotenone and cycad-induced PD rat models mimic
sleep disturbances seen in humans prior to the onset of clinical
symptoms of PD, but produce exceedingly mild locomotor
dysfunction that are both bilateral and symmetric, unlike what is
observed in human PD.33,34 Similarly, intranasal or direct
intranigral administration of lactacystin, a natural proteasome
inhibitor fails to produce stable parkinsonism while causing RBD in
the rat.35 While several studies have shown that inactivation of the
glutamatergic neurons of the sublaterodorsal nucleus in rat
models results in RSWA,36–39 the occurrence of RBD is most often
seen in the early stages of PD when there is very little evidence of
damage to this region. Moreover, the role of nigrostriatal
degeneration, the dominant pathophysiology seen in PD, on
RBD associated with PD is not explained by these models. In
contrast, the hemiparkinsonian rat model displays this hallmark
degeneration of the nigrostriatal dopaminergic pathway and the
unilaterality of motor deﬁcits, which can be characterized using
well-established tests that have been extensively validated. Since
PD always begins with unilateral symptoms (stage I disease), the
6-OHDA lesioned hemiparkinsonian rat simulates this natural
disease progression as well. Crucially, we have previously shown
that the sleep architecture in this rat model resembles that of PD
patients and may thus be useful to elucidate the pathophysiological basis of PD sleep disturbances and be useful to test
experimental therapies for RBD in early PD.22
While some rudimentary species-speciﬁc sleep postures and
behaviors have been reported previously, most pre-clinical models
of PD lack a codiﬁed rodent equivalent of human behaviors that
are commonly associated with RBD.40–44 This issue is exacerbated
by the lack of standard PSG recording procedures and sleep stage
classiﬁcation in stark contrast to the well-accepted methods
commonly applied to human sleep studies.45 Our paper provides
such a well-deﬁned behavior-based criterion for sleep-stage
classiﬁcation in rodents with time-locked PSG recordings that
has been validated and tested with experimental therapeutics. A
review of sleep staging systems in rats21 indicate that with few
exceptions46,47 most sleep studies classify REM sleep as a single
stage which could lead to an inaccurate classiﬁcation of RSWA. In
contrast, the use of EOG recordings and a stringent two standard
deviation deﬁnition for positive muscle activity in the present
study allows for the bifurcation of REM sleep into its tonic and
phasic components and consequently accurately identify RSWA.
Further, the use of a behavior-based criteria in conjunction with
polysomnography recordings is also in line with newer scales used

Fig. 6 Representative photomicrographs of tyrosine hydroxylase immunohistochemistry from hemiparkinsonian rats. a Mid striatal coronal
section showing nearly complete dopaminergic denervation of the left striatum and intact nigrostriatal innervation of the right striatum.
b Section through the substantia nigra demonstrating near complete denervation in the lesioned (left) side and an intact contralateral (right)
side. Scale bar: 500 µm.
Published in partnership with the Parkinson’s Foundation
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to detect and quantify RBD in humans such as the REM Sleep
Behavior Disorder Severity Scale.48
There is a plethora of evidence that shown that the
dopaminergic neurons present in the substantia nigra pars
compacta (SNpc) play an important role in the regulation of
REM sleep in rats.49–51 These neurons receive inputs from the
locus coeruleus (REM-OFF) and laterodorsal/pedunculopontinetegmentum (REM-ON), neurons which could modulate the
presence of RBD.52 Hemiparkinsonian rats also show reduced
ratios of distance and transitions between the resting vs. the
activity phase, which could potentially parallel similar abnormalities seen in RBD associated with PD.36 A variety of underlying
mechanisms including dopamine release from the unlesioned
hemisphere, disruptions in the mesopontine dopaminergic
neurons, and excessive nigral GABAergic inhibition via the
pedunculopontine nucleus (PPN) have been proposed for these
REM sleep disturbances seen in hemiparkinsonian rats.49,53–56
Number of studies also suggest that divergent midbrain
dopaminergic populations have different effects on sleep-wake
regulation and RSWA. Dopaminergic cells that originate in the
ventral tegmental area and the dorsal raphe have been implicated
as key arousal promoting systems, which are counterbalanced in
health by SNpc dopaminergic neurons that promote sleep.57 The
lesioning of SNpc dopaminergic neurons may therefore create an
imbalance that contributes to RSWA and the RBD-like features in
the hemiparkinsonian rat model. In spite of several lines of
evidence indicating a dopaminergic basis for the development of
RBD in PD, few studies have analyzed the effects of dopamine
replacement therapy on this sleep dysfunction in the context of a
preclinical model of PD.
Studies have suggested that the presence of RBD in PD may put
patients at higher risk for levodopa-induced motor ﬂuctuations in
wakefulness.58–61 This ﬁnding may indicate that PD patients with
concomitant RBD have a more severe form of neurodegeneration
or that RBD is an at-risk biomarker for motor ﬂuctuations in PD.
Recent studies have proposed that many of the deleterious effects
of levodopa treatment can be minimized by modifying dosing
regimens to provide continuous dopaminergic stimulation.62–64
The varying regimens in the current study were formulated based
on pharmacodynamics of levodopa to test the effects of
intermittent oscillating versus continuous non-oscillating dosing
schedules. Fluctuations in levodopa concentrations caused by
conventional BID and TID dosing regimens have been shown to
result in wider oscillations in striatal dopamine availability causing
profound pathophysiological alterations in the basal ganglia
which in turn cause motor complications and RBD.65–67 We show
here that ATC dosing regimen at 4-h intervals potentially
overcomes the issue of oscillating levels of striatal dopamine
and thereby mitigates daytime motor deﬁcits and night time
RSWA. The relationship between these two beneﬁcial effects of
ATC levodopa dosing to mitigate PD-related phenomenology
requires further study.
Our observations are further strengthened by recent clinical
studies where levodopa/carbidopa intestinal gel was administered
via intrajejunal pump continually for 24 h.25,68,69 In these patients,
there was a signiﬁcant overall improvement in their sleep quality
as measured by the Parkinson’s Disease Sleep Scale and NonMotor Symptoms Scale consistent with improvement of nocturnal
akinesia.69 Studies also show that sleep abnormalities are not
adequately addressed with optimized daytime dosing of medication and that untreated sleep disturbances have alarming
consequences for daytime function in PD patients. New treatment
approaches in treating PD patients therefore, recommend the
utilization of 24-h continuous treatment strategies used here to
sufﬁciently manage and control both daytime and nighttime
symptoms.70–72 Advances in formulations and routes of administration have allowed for such treatments in PD patients and
suggest that ATC dopamine agonist therapies may provide
npj Parkinson’s Disease (2019) 27

beneﬁts to subjective measures of sleep.73 Recent studies of
rotigotine, a highly lipophilic dopamine-receptor agonist delivered
via transdermal patches has been shown to improve subjective
sleep quality in PD patients with RBD74 and was found to be
effective in both early75 and advanced stage PD patients.76 The
dopamine agonist, ropinirole in its 24-h prolonged release
formulation has been found to efﬁcacious in improving nocturnal
symptoms of PD in double-blind, placebo-controlled trials.77,78
Similarly, intrajejunal infusions of levodopa–carbidopa intestinal
gel (Duodopa) has also been shown to improve sleep quality in PD
patients.69,79 These new advances in routes of administration lead
to 24-h, continuous, nonﬂuctuating drug levels and may therefore
help ameliorate RBD in PD.
There are some drawbacks to our study that need to be
addressed. Only a low-to-medium range of levodopa doses were
tested in the current study. This is in keeping with the dose of
levodopa that is typically employed in early PD patients. Testing
higher dosages of levodopa may be useful to further clarify its
effects on RBD in future studies. Though animals had wellestablished baseline recordings and a washout period between
dosages of LD our study lacks a cohort of vehicle injected animals.
However, our before and after study design does provide the
proof of principle to undertake additional longer studies that
include separate control groups. Studies that include longer
segments of PSG and video recordings with multiple camera
angles may have additional beneﬁts and help further elucidate the
behavior-based criteria described here. Future studies that utilize
osmotic minipumps or other methods for continuous levodopa
delivery as shown in a recent study80 may be utilized to further
test the feasibility of our ATC levodopa therapeutic approach. The
behavior-based criteria reported here requires well-trained and
experienced raters and is labor intensive. Many hours of training
were needed for the raters to learn the behavior-based criteria.
Future studies could also try to implement the use of computational software to allow for automatic classiﬁcation that will permit
ease of use. Finally, the use of telemetric implantable devices that
permit the use of cardiac, respiratory, and jaw muscle group
monitoring were not available for polysomnographic classiﬁcation
in the current study and may have added advantages in future
studies.
In conclusion, our ﬁndings support the dopaminergic mechanisms for RBD, an important non-motor aspect of PD. The
characterization of RBD as a non-motor aspect of PD does
represent a paradox, despite its continued characterization as such
in most PD literature. This is because, movement and tone
abnormalities are the key aspects of RBD, and they are indeed
motor phenomena albeit occurring during sleep. Our study in the
hemiparkinsonian rat (which has exclusive lesioning of the
nigrostriatal pathway with preservation of other relevant monoamine systems due to the use of desipramine during lesioning)
suggests that the nigrostriatal dopaminergic pathway may play a
seminal role in RBD and sleep disturbances seen in this PD model
as reported elsewhere.51,81,82 Our ﬁndings suggest that dopamine
dysregulation contributes to RSWA and that normalizing this with
ATC dopaminergic replenishment mitigates this sleep abnormality. Our results show that ATC levodopa dosing modulates REM
sleep disturbances much better than intermittent BID or TID
dosing. The use of ATC dopamine administration and its ability to
provide non-ﬂuctuating levels of dopamine replenishment could
help cover both daytime and nighttime symptoms of PD. The
advent of new drug-delivery systems such as intra-jejunal
levodopa gel infusion therapy and transdermal dopaminergic
patches could translate these ﬁndings to beneﬁt PD patients. We
also propose behavior-based criteria that resembles behavior
rating scales for RBD in humans and could help facilitate studies
into the mechanisms underlying RBD in PD using this animal
model. Since RBD could potentially be a harbinger of PD, this
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animal model-based criteria could have broad applicability for the
development of effective neuroprotective therapies.
METHODS
Twenty-two female Sprague–Dawley rats weighing 220–250 g at the time
of acquisition and housed on a 12-h light:dark cycle (8 am–8 pm) with ad
libitum access to food and water were used in the experiment. All
procedures were carried out in accordance with the guidelines in the NIH
Guide for the Care and Use of Laboratory Animals and were approved by
the Pennsylvania State University Institutional Animal Care and Use
Committee. A set of normal rats were used to create the behavior-based
criteria (n = 3) and the remaining rats were randomly assigned to either
the hemiparkinsonian (n = 9) or unlesioned control (n = 10) groups. Rats in
the hemiparkinsonian group were further randomly subdivided into an
untreated (n = 5) and levodopa-treated (n = 4) groups.

Lesioning surgery
Hemiparkinsonism was induced in nine rats by lesioning the left
nigrostriatal pathway using a modiﬁed version of the Ungerstedt model.83
Brieﬂy, 6-hydroxydopamine-hydrogen bromide (12 μg in 4 μl) was stereotactically injected into the medial forebrain bundle (antero-posterior (AP):
−1.5 mm, medio-lateral (ML): +1.8 mm, dorso-ventral (DV): −7.5 mm from
bregma, the midline suture and the skull surface, respectively) at a rate of
0.67 μl/min using a gastight Hamilton syringe, following which the needle
was left in place for 5 min. Prior to the surgery, rats received an injection of
the noradrenergic uptake blocker desipramine (15 mg/kg i.p.) to avoid
damage to norepinephrine (NE) pathways and to limit the lesion effect to
the SNpc in one hemisphere. After 3 weeks of recovery, the lesioned rats
were challenged twice, 2 weeks apart with apomorphine hydrochloride
(0.2 mg/kg, s.c.). The apomorphine-induced rotations were counted in an
automated ‘rotometer’ (San Diego Instruments). Rats with more than 245
rotations over 35 min on two separate sessions were classiﬁed as
hemiparkinsonian rats and used in the study.84 Ten rats did not receive
the lesioning surgery and were used as controls.

Electrode implantation surgery
Subsequently, all rats were implanted with stainless-steel skull screws over
the frontal and parietal cortices for electroencephalograph (EEG) recordings, a pair of wire electrodes in the nuchal muscles for electromyograph
(EMG) recordings and two screws in the supraorbital ridge for electrooculograph (EOG) recordings under general anesthesia as described
previously.85,86

Polysomnography recordings
After recovery from surgeries, polysomnography (PSG) comprising of EEG,
EMG, and EOG recordings was obtained, analyzed, and averaged to obtain
equal “lights-on” and “lights-off” recording times for all rats. Signals were
ampliﬁed and ﬁltered with a Grass Model 12 Neurodata ampliﬁer system
(Grass Instrument Division of Astro-Med, Inc., West Warwick, RI), and
digitized at 128 Hz with a USB-2533 16-bit analog to digital converter
(Measurement Computing Corporation, Norton, MA). The EEG, EMG, and
EOG signals were ﬁltered ofﬂine in Matlab (Mathworks), segmented into
10-s epochs, and manually rated using the commercial SleepWave
program (Biosoft Studio, Hershey, PA). The behavior criteria development
relied on EEG and EMG recordings alone to classify each 10-s epoch as
demonstrative of wakefulness, NREM sleep, and REM sleep.22 Subsequently, to study RSWA, the REM sleep component was further divided
into tonic REM sleep and phasic REM sleep using EOG recordings
(described below).

REM sleep classiﬁcation
Baseline PSG recordings (24 h each) were obtained from all rats and were
aligned to the 12-h light/dark cycles after which the rats received levodopa
(described below). The rats were then recorded to obtain post levodopa
PSG. Sleep-wake classiﬁcation was carried out using only EEG and EOG
recordings. EOG recordings were further used to differentiate REM sleep
into its phasic (characterized by bursts of EOG spikes) and tonic
components (characterized by periods of little or no EOG activity
components) (Fig. 7). EMG was used to evaluate for positive muscle
activity, deﬁned as muscle activity during tonic REM sleep that was two
Published in partnership with the Parkinson’s Foundation

Fig. 7 Polysomnography patterns of phasic and tonic REM of an
hemiparkinsonian animal, including 2 EEG, 1 EOG, and 1 EMG
channels. a Muscle activity during phasic REM, characterized by
presence of EOG and EMG activity (normal); b Atonia during tonic
REM, characterized by lack of EOG and EMG activity (normal);
c Muscle activity during tonic REM, or REM sleep without atonia
(RSWA), characterized by the lack of EOG activity and presence of
EMG activity, which is representative of RBD in rats.
standard deviations above the baseline atonia. The percentage of tonic
REM with positive muscle activity was determined and compared between
baseline and each levodopa dosing regimen.

Levodopa dosing regimens
All levodopa-treated hemiparkinsonian rats (n = 4) received injections of
levodopa and benserazide, on separate occasions at two different doses,
2 mg/kg or 4 mg/kg, of levodopa and 15 mg/kg benserazide (i.p.).
Benserazide has been shown to inhibit peripheral aromatic L-amino acid
decarboxylase (AADC) activity, enhance brain bioavailability of levodopa,
and increase extracellular striatal dopamine levels in hemiparkinsonian
rats.87 Microdialysis studies in unlesioned rats88–91 and hemiparkinsonian
rats87,92 show that levodopa plus benserazide signiﬁcantly increases levels
of extracellular dopamine in the striatum for up to 4 h post injection
compared to baseline levels. Three different dosing regimens were utilized:
BID, TID, and ATC every 4 h for 24 h (Supplementary Fig. 1). The ﬁrst
injection of each dosing regimen was aligned with the lights-on time of
8 am. The BID levodopa injections were administered at 8 am and 4 pm.
The TID levodopa injections were administered at 8 am, 12 pm, and 4 pm.
Finally, the ATC levodopa injections were administered at 8 am, 12 pm,
4 pm, 8 pm, 12 am, and 4 am. The overall daily dosage of levodopa that
npj Parkinson’s Disease (2019) 27
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each animal received was constant and was sub-divided into parts
depending on the dosing regimen being used. The BID and TID doses were
given only during the 2-h lights-on phases as rats were more likely to be in
REM sleep. All rats in the levodopa treatment group received 2 days of
injections of all dosing regimens, which were separated by washout
periods of 24 h to analyze the effects of each one independently. PSG
recordings were obtained for all sessions spanning about 48 h of
recordings from each rat for each dosing regimen. All rats were
acclimatized to injections prior to the start of any experimentation and
after were continually observed after each injection until they resumed
their previous behavioral state.

Behavior-based criteria development
To create a set of behavior-based criteria, video recordings were timelocked with PSG recordings of a cohort of normal rats (n = 3). Video
recordings were then reviewed and the behaviors of the animals in each
stage were recharacterized by a blinded rater. Video observations and
complementary PSG recordings of rats showed six distinct behaviors
characterizing the three sleep-wake stages (Table 3). Wakefulness was
characterized by behaviors including arousal posture (bipedal activity,
eating, posture of the extended tail, whisking, and grooming); NREM was
characterized by closed eyes, stationary position, tail not extended, and
chin resting on tail or ground; and REM was characterized by the sleepslouch. The sleep-slouch was a movement of the rat’s body, head, or both to
one side of the body caused by gravity rather than active muscle
contraction (Supplementary Video 1). This phenomenon served as a
behavioral correlate of REM sleep and was followed by RSWA in
hemiparkinsonian rats. A score (Table 3) was assigned to each behavior
in correlation with PSG that resulted in a total score at any time point
denoting the current sleep-wake stage of the rats.

Behavior-based criteria vs. PSG recordings and inter-rater
agreement
To test the behavior-based criteria against the gold standard of PSG, hourlong video recordings from the lights-on periods of control rats were
scored by a blinded rater (Scorer 1) using the behavior-based criteria. A
second rater (Scorer 2) was then used to test the inter-rater reliability of the
behavior-based criteria. The percentage of time spent in each sleep-wake

stage was calculated and averaged between the Scorer 1 and Scorer 2,
then compared to that obtained from EEG/EMG alone without the use of
EOG recordings. To determine whether any agreement is reﬂective of the
actual sleep-wake patterns, the sleep proﬁles were graphed and compared
to those obtained from PSG. In all graphing of the stages of wakefulness,
the stages were split into 10-s epochs with REM receiving the highest
priority in the instance of an epoch containing more than one sleepwake stage.
This comparison with PSG was again performed on the hemiparkinsonian and the levodopa-treated hemiparkinsonian rats using a blinded rater.
Given the unreliability of EMG in the presence of RSWA-like behaviors in
hemiparkinsonian rats (movement artifacts), this comparison was performed using the EEG and EOG recordings against the rater for the
untreated hemiparkinsonian group and the levodopa treated hemiparkinsonian group. CCC with 95% CI was calculated to assess agreement i.e.
reliability for all comparisons. The level of probability for good agreement
was set at a CCC >0.8.

Vibrissae-evoked forelimb placement test
To evaluate the efﬁcacy of levodopa treatment on forelimb motor deﬁcits,
rats underwent the vibrissae-evoked forelimb placement test93 at the end
of each dosing regimen. Previously, we have shown that hemiparkinsonian
rats show profound deﬁcits on this test after lesioning and that these
deﬁcits were ameliorated by levodopa/benserazide treatment.94 Since
testing in the current study was performed during the lights-on period
when the animals are less active, we chose this evoked test as a measure of
forelimb function. The rats were tested immediately following one of the
last injections to test the drug at maximum efﬁcacy and separated from
any polysomnographic recordings that were utilized for analysis from
these animals. Brieﬂy, animals were held at the torso so that the hind limbs
and the forelimb being tested could hang freely while the forelimb not
being tested was carefully restrained. The unrestrained forelimb was
evaluated by bringing the rat toward the edge of the tabletop to elicit an
evoked reaching behavior toward the surface due to stimulation of the
ipsilateral vibrissae contact with the table surface. This response was tested
for each forelimb independently for ten trials and repeated three times.
The number of successful placements for each forelimb onto the tabletop
was scored to determine the percentage of affected forelimb usage.

Histology
Table 3. Six signs comprising the behavior-based criteria for sleepwake stage classiﬁcation.
Behavioral-based criteria: Signs

Score

Arousal posture:
Moment of temporary wakefulness characterized by quick jerky
motions indicative of muscle contractions, extension of a limb,
rising of the head, and elevation of the back

−2

Eyes closed:
The black of the rat’s pupil is completely covered by the eyelids
such that the top and bottom lids are touching
No movement for a period of ≥5 s:
The entire body remains still for a period of ≥5 s
Tail not extended:
The tail is coiled around the body such that the tip of the tail is
anterior to where the tail exits the body. The angle at which the
tail leaves the body is <90°. The tail must be touching the body
at a point anterior to the root of the tail

1

Chin resting on tail or ground:
The chin is reclining on the ground, tail, or on another structure
so as to not be elevated

1

Sleep-slouch posture:
Movement of a rat’s body, head, or both that occurs during
sleep, caused only by gravity acting on a part of the body, not
by contraction of muscle

3

Stereology

1

Estimates of tyrosine hydroxylase positive neurons in the substantia nigra
was performed using a design-based optical fractionator method (Stereo
Investigator, MBF Bioscience) on the unlesioned right substantia nigra,
using systematic random sampling and unbiased stereological estimation.
The Abercrombie correction to manual physical counts was applied when
counting procedures did not meet the criteria for the optical fractionator
as was the case with the lesioned left substantia nigra.95

1

Statistical analysis

Scoring for the behavior-based video criteria used the following rubric: ≤1:
indicates wakefulness, 2–4: indicates non-REM (NREM) sleep, and ≥5:
indicates REM sleep
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At the end of the study, all rats were euthanized via transcardiac perfusion
with cold heparinized saline and 4% paraformaldehyde ﬁxative. Brains
were removed, cryoprotected, and sectioned coronally at 60 µm. Sections
were processed for cresyl violet (Nissl stain) and tyrosine hydroxylase
immunohistochemistry to verify unilateral depletion of the nigrostriatal
pathway as described previously.94

All statistical analysis was performed by an investigator who was blinded
to all experiments on animals, polysomnographic and behavioral raters to
avoid any bias (A.K.). For additional rigor, histological analysis and
stereology was performed by investigator blinded (K.V.) to all other
experimental assessments. CCC with 95% CI was calculated using R
software, version 3.5.1 (The R Foundation for Statistical Computing, Vienna,
Austria) to assess inter-rater reliability between raters and to assess face
validity between polysomnography and the criteria. The level of good
agreement was set at a CCC >0.8.
One-way ANOVA followed by Dunnett’s multiple comparisons test was
calculated using GraphPad Prism version 7.05 for Windows, GraphPad
Software, La Jolla, California, USA, www.graphpad.com, that accounts for
the within-animal correlation of multiple levodopa doses per rat, was used
for analysis of the behavioral assessment, the percentage of tonic REM
epoch with muscle activity between baseline and each levodopa dose and
Published in partnership with the Parkinson’s Foundation
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the total REM epoch. Data are expressed as mean ± SEM and the level of
probability for statistical signiﬁcance was set at 0.05.

Reporting Summary
Further information on research design is available in the Nature Research
Reporting Summary linked to this article.

DATA AVAILABILITY
The data used to support the ﬁndings of this study are available from the
corresponding author upon request.
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